Latest News - Johnson & Johnson
Top Corporates Hub
Johnson & Johnson
Buy 5 Wide Moat Stocks to Enhance Your Portfolio Returns
01.08.2025 11:15
Boost your portfolio with ADBE, DIS, INTU, ROL and JNJ as these five wide moat stocks poised for growth and strong returns.
Johnson & Johnson Stock: Analyst Estimates & Ratings
01.08.2025 07:52
Johnson & Johnson has outpaced the broader market and the healthcare sector in 2025, and analysts remain optimistic about the stock’s prospects.
Johnson & Johnson’s (JNJ) Long Dividend History Makes it a Strong Retirement Dividend Stock
01.08.2025 02:29
Johnson & Johnson (NYSE:JNJ) is included among the 10 Best Dividend Stocks to Buy for Retirement. Johnson & Johnson (NYSE:JNJ) stands out as a financially strong company, being one of only two firms globally with a perfect AAA credit rating, higher than that of the US government. By the end of the second quarter, it […]
Merz Aesthetics Strengthens U.S. Commercial Leadership With Key Executive Hires
30.07.2025 12:05
RALEIGH, N.C., July 30, 2025--Merz Aesthetics, the world’s largest dedicated medical aesthetics business, today announced two additions to its North America regional executive team: Chris Van Dyk, Vice President of U.S. Sales, and DJ Sethares, Vice President of U.S. Marketing. In their new roles, Van Dyk and Sethares will oversee all sales and marketing efforts, respectively, to drive growth across the Merz Aesthetics portfolio of brands in the United States.
[Latest] Global Lenacapavir Injection Market Size/Share Worth USD 5.68 Billion by 2034 at a 5.1% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
30.07.2025 08:30
[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Lenacapavir Injection Market size & share revenue was valued at approximately USD 3.5 Billion in 2024 and is expected to reach USD 3.66 Billion in 2025 and is expected to reach around USD 5.68 Billion by 2034, at a CAGR of 5.1% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Gilead Sciences, Dr. Reddy’s
Johnson & Johnson Launches VIRTUGUIDE™ AI-Powered Patient-Matched Lapidus System in U.S. to Reduce Complexity in Bunion Surgery for Millions
29.07.2025 12:03
Johnson & Johnson (NYSE: JNJ) – Johnson & Johnson MedTech, a global leader in orthopaedic technologies and solutions, today announced the launch of the VIRTUGUIDE™ System. This AI-powered, patient-matched solution is designed to support Lapidus procedures2, a type of bunion surgery that helps realign the foot by joining two bones near the arch (the first metatarsal bone and the medial cuneiform).3 The system uses pre-operative planning software, developed in collaboration with PeekMed®, to asses
Cybersecurity Trailblazer Marene Allison Joins Sicura as Strategic Advisor to Advance Security Control Management
29.07.2025 12:02
Sicura, defining the future of Security Control Management, today announced that Marene Allison, former chief information security officer (CISO) at Johnson & Johnson, has joined the company as a strategic advisor. With four decades of experience protecting some of the world's most sensitive environments, Allison will offer Sicura critical strategic support for product, go-to-market and industry engagement.
Johnson & Johnson files with U.S. FDA to include new evidence in TREMFYA® (guselkumab) label as the only IL-23 inhibitor to demonstrate significant inhibition of joint structural damage in active psoriatic arthritis
29.07.2025 12:00
Johnson & Johnson (NYSE: JNJ) today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval to include new evidence in the TREMFYA® (guselkumab) label for the inhibition of progression of structural damage in adults with active psoriatic arthritis (PsA).
Merck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2025 Financial Results
29.07.2025 10:30
RAHWAY, N.J., July 29, 2025--Merck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2025 Financial Results
New Drug, New Direction: J&J Moves Deeper Into Late-Stage Therapeutics
29.07.2025 06:06
Johnson & Johnson (NYSE:JNJ) is one of the best trade‑war resistant stocks to buy now. On July 21, 2025, J&J submitted a New Drug Application to the U.S. FDA for icotrokinra, an oral peptide therapy targeting moderate to severe plaque psoriasis in patients aged 12 and older—signaling a strong late‑stage R&D pipeline with growth potential beyond consumer […]
Johnson & Johnson (JNJ) Upgraded to Buy as Growth and Margins Impress Analysts
29.07.2025 05:37
Johnson & Johnson (NYSE:JNJ) ranks among the stocks to benefit from an onshoring boom. On July 23, Erste Group raised the stock rating of Johnson & Johnson (NYSE:JNJ) from Hold to Buy. The firm attributed the upgrade decision in large part to Johnson & Johnson’s superior operating margin and return on equity when compared to […]
2 Unstoppable Dow Dividend Stocks to Buy and Hold Forever
29.07.2025 00:29
These top Dow dividend stocks have long dividend growth streaks.
Got $1,000? 3 High-Yield Healthcare Stocks to Buy and Hold Forever
29.07.2025 00:05
If you're looking for high-yield stocks in the healthcare sector, it's hard to beat this trio of industry giants offering yields of up to 3.9%.
GSK: I Foresee Only Very Modest Upside Here Even If Blenrep Gets FDA Approval
28.07.2025 12:41
GSK's stable dividend and strong portfolio face modest growth amid competition and legal risks.
22 Dividend Kings At Discounted Valuations
27.07.2025 12:14
Discover 3 dividend kings offering reliable income growth and capital appreciation.
Mountain Valley MD Holdings Announces Changes to Board of Directors
24.07.2025 01:49
TORONTO, July 24, 2025--Mountain Valley MD Holdings Inc. (the "Company" or "MVMD") (CSE: MVMD) (OTCQB: MVMDF) (FRA: 20MP) is pleased to announce the appointment of David Batchelor to its board of directors.
European Commission approves DARZALEX® (daratumumab) as the first licensed treatment for patients with high-risk smouldering multiple myeloma
23.07.2025 09:30
Landmark approval is based on results from the Phase 3 AQUILA study, showing fixed-duration treatment with daratumumab significantly reduced the risk of progression to active multiple myeloma or death by 51 percent compared to active monitoring1 This milestone marks a critical advance in early intervention for multiple myeloma as the first authorised treatment, offering a new treatment paradigm for patients with high-risk smouldering disease2 Beerse, Belgium, July 23, 2025 (GLOBE NEWSWIRE) -- Ja
European Commission approves IMBRUVICA® (ibrutinib) as the first targeted therapy for patients with previously untreated mantle cell lymphoma who would be eligible for autologous stem cell transplant
23.07.2025 09:06
Ibrutinib is the first approved Bruton’s tyrosine kinase (BTK) inhibitor to demonstrate statistically meaningful outcomes versus autologous stem cell transplant (ASCT) for the frontline treatment of transplant eligible patients with mantle cell lymphoma1 Data from the Phase 3 TRIANGLE study defines the fixed-duration ibrutinib-based regimen as a new standard of care (SOC) with significantly improved overall survival and failure-free survival versus ASCT1 BEERSE, BELGIUM, July 23, 2025 (GLOBE NEW
Ipsen announces changes to its Executive Committee
23.07.2025 05:30
PARIS, FRANCE, 23 July 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty care biopharmaceutical company, today announced the following changes to its Executive Committee: Mari Scheiffele is appointed to EVP, Chief Product OfficerAndreas Gerber is appointed to EVP, Head of InternationalCaroline Sitbon is appointed to EVP, General Counsel Mari, Andreas and Caroline will report to Ipsen’s Chief Executive Officer, David Loew, beginning September 1, 2025. After 4 years successfully leading
Kenvue: Tylenol Can't Ease The Pain, Pricey Stock, Dividend In Vain
22.07.2025 05:30
Kenvue faces challenges with declining sales, cash flow risks, and high leverage. Read here for more analysis on KVUE stock.